Accessibility Menu
Valneva Se logo

Valneva Se(OTC) INRLF

Market Cap$459.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-20%
5 Year-83%
1 Year-37%
1 Month-7%
$2.43
+0.00%
+0.00Today
Valneva Se last closing stock price
MetricPriceDate
Last closeUSD 2.432026-07-30
Valneva Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.44%USD 2.622026-07-17
1 month-7.44%USD 2.622026-06-29
3 month-23.06%USD 3.152026-04-22
Year to date-42.28%USD 4.202025-12-31
1 year-36.62%USD 3.832025-07-30
3 year-67.5%USD 7.462023-07-31
5 year-82.96%USD 14.232021-07-30
Since inception-19.83%USD 3.032017-01-30

Valneva Se Financials at a Glance

Market Cap

$459.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€156.45M

Net Income (TTM)

-€138.15M

EPS (TTM)

-$0.94

P/E Ratio

-2.59

Dividend

$0.00

Beta (Volatility)

0.39 (Low)

Price

$2.43

Volume

325

Open

$2.43

Previous Close

$2.43

Daily Range

$2.43 - $2.43

52-Week Range

$2.43 - $6.28

Estimated Earnings Date

Aug 13, 2026

INRLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Valneva Se

Valneva SE is a specialized biopharmaceutical company focused on developing and commercializing preventative vaccines for infectious diseases. The company aims to address unmet medical needs in the vaccine market, particularly for international travelers and emerging infectious diseases.

Products and Services
  • IXIARO: A vaccine for Japanese encephalitis
  • DUKORAL: An oral vaccine for cholera and E. coli
  • VLA15: A Lyme disease vaccine candidate in Phase II trials
Growth Outlook
  • VLA2001, a COVID-19 vaccine, has shown promising results
  • Strategic partnerships with Pfizer and Instituto Butantan enhance development capabilities
  • Expansion into new markets is anticipated, increasing global reach
Financial Highlights
  • Recent quarterly revenue of €31 million indicates potential growth
  • Cash reserves of €105 million provide a buffer for ongoing R&D
  • TTM gross profit margin of 29% reflects operational efficiency
Valneva SE operates in a dynamic sector with a focus on innovative vaccine solutions. The company’s existing products, such as IXIARO and DUKORAL, cater to specific health needs, while its pipeline includes promising candidates like VLA15 and VLA2001. Recent financial data shows a quarterly revenue of €31 million, suggesting a positive trajectory. With cash reserves of €105 million, Valneva is well-positioned to support its research and development efforts. The strategic partnerships with major pharmaceutical companies further enhance its potential for growth and market expansion. Overall, Valneva SE represents an intriguing opportunity in the biotechnology sector, particularly for those interested in vaccine development and infectious disease prevention.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

674

CEO

Thomas Lingelbach, PhD

Website

www.valneva.com

Headquarters

Saint-Herblain, GE 44800, FR

INRLF Financials

Key Financial Metrics (TTM)

Gross Margin

29.46%

Operating Margin

-68.81%

Net Income Margin

-88.30%

Return on Equity

-106.22%

Return on Capital

-26.05%

Return on Assets

-37.10%

Earnings Yield

-38.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$459.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

189.65M

Volume

325

Avg. Volume

182.889

Financials (TTM)

Gross Profit

€46.07M

Operating Income

-€101.40M

EBITDA

-€81.69M

Operating Cash Flow

-€49.20M

Capital Expenditure

-€3.26M

Free Cash Flow

-€52.45M

Cash & ST Invst.

€105.66M

Total Debt

€210.30M

Valneva Se Performance Analysis

Valneva Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 379,720,174-7.7%
20232023-12-31EUR 166,181,523-56.2%
20242024-12-31EUR 183,432,03710.4%
20252025-12-31EUR 197,116,2967.5%
Valneva Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.8%
Q32025-09-30-39.1%
Q42025-12-3162.2%
Q12026-03-31-34.9%
Valneva Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.3046.7%
20232023-12-31EUR -0.79-39.3%
20242024-12-31EUR -0.09-88.5%
20252025-12-31EUR -0.77750.4%
Valneva Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-25.5%
Q32025-09-30-245.3%
Q42025-12-31-11.5%
Q12026-03-3134.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€31.02M

-37.0%

Gross Profit

€4.74M

-81.9%

Gross Margin

15.29%

N/A

Market Cap

$459.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$682.34K

N/A

Employees

674

N/A

Net Income

-€32.19M

-248.7%

EBITDA

-€20.31M

-1041.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€105.66M

-30.9%

Total Debt

€210.30M

-0.4%

Accounts Receivable

€10.17M

-69.7%

Inventory

€50.78M

-17.7%

Long Term Debt

€189.21M

+0.2%

Short Term Debt

€21.01M

-6.2%

Return on Assets

-37.10%

N/A

Return on Invested Capital

-38.72%

N/A

Free Cash Flow

-€4.70M

+51.2%

Operating Cash Flow

-€4.45M

+45.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOLTFNxera Pharma Co., Ltd.
$5.73+1.74%
VBIZFViva Biotech Holdings
$0.16+0.00%
BPMUFBasilea Pharmaceutica AG
$60.28+0.00%
MDRXVeradigm Inc.
$4.80-4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About INRLF

What is the current price of Valneva Se?

Valneva Se is trading at $2.43 per share.

What is the 52-week range for Valneva Se?

Over the past 52 weeks, Valneva Se has traded between $2.43 and $6.28.

How much debt does Valneva Se have?

As of the most recent reporting period, Valneva Se reported total debt of €241.39M.

How much cash does Valneva Se have on hand?

Valneva Se reported €121.29M in cash and cash equivalents in its most recent financial results.

What is Valneva Se’s dividend yield?

Valneva Se does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services